Galderma news. 7% stake in the skincare group that could raise around 1.
Galderma news Feb 14, 2025 · Galderma has won approval from the European Commission (EC) for subcutaneous injection Nemluvio (nemolizumab) for the treatment of atopic dermatitis (AD), becoming the latest pharmaceutical company to enter the lucrative market for the skin disorder. 28 billion Swiss francs ($1. . government in order to manage their impact, CEO Flemming Ornskov said on Thursday. S. 7% stake in the skincare group that could raise around 1. 3 billion Swiss francs ($2. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Revolutionizing Atopic Dermatitis 2025 Conference: Galderma’s Scientific Presentations Galderma buys back shares worth CHF 233 million in the Mar 6, 2025 · Swiss skincare company Galderma will talk to major American retailers about trade tariffs imposed by the U. Galderma said that its public offering was its “next step Jun 6, 2025 · Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. 6 billion). News story . 45 billion), according to terms of the deal seen Aug 13, 2024 · In March, when Galderma was listed on the SIX Swiss Exchange, it drew an investment of nearly 2. Aug 5, 2024 · ZUG, Switzerland, August 05, 2024--Galderma today announced that it has signed a memorandum of understanding with L’Oréal to work towards a new research and development (R&D) collaboration in Nov 20, 2024 · Several Galderma Group AG shareholders are offering about a 6. pemmebnptcupztjlifnqiidjkfrdqqzboutkiqzjfbuopif